Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-01-05

FDA Approved: LISDEXAMFETAMINE DIMESYLATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)

View source ↗

Summary

FDA approved Sun Pharmaceutical's supplemental application for lisdexamfetamine dimesylate, a generic version of the ADHD medication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LISDEXAMFETAMINE DIMESYLATE (Lisdexamfetamine dimesylate)

Snippet

SUPPL AP for LISDEXAMFETAMINE DIMESYLATE (LISDEXAMFETAMINE DIMESYLATE)